NEJM why would #immunotherapy work better when given before surgery (neoadjuvant) when the tumor is still in the body?

🔪 Resection not only takes bulk of the tumor but also the tumor-infiltrating lymphocytes.

⬆️T cells to antigens exposure.
OncoAlert

nejm.org/doi/full/10.10…

#AUA24 Amer. Urol. Assn. annual meeting-plenary👉Joshua Meeks ‘s excellent talk on challenges of neobladder👉Who should get a neobladder after radical surgery for #bladdercancer ?👇quote by W Buffett: the secret to happiness in life is low expectations OncoAlert SWOG Cancer Research Network Seth lerner

So proud of my fellow Uromigo!!

💫🌟 🆕️Recent study on muscle-invasive bladder cancer compares trimodal therapy (TMT) and radical cystectomy (RC):
OncoAlert  Francesco Ditonno Alessandro Antonelli Simone Crivellaro Alexander Kutikov MD
GU Cast | Urology podcast!

🔄 No significant differences found in overall survival (OS) between TMT and RC,…

Well deserved Tom Powles. Tom is a visionary who has helped changed the landscape of therapy for #BladderCancer & #kidneycancer with innovative thinking and at the same time pragmatism with #clincialtrials . Terrific to see him on this list. Brian Rini, MD Toni Choueiri, MD Matt Galsky…

The #FDA announced new guidance to expand eligibility criteria with the goal of improving participation and diversity in oncology clinical trials. These 3 areas of change include laboratory values, washout periods, and performance status.

targetedonc.com/view/new-fda-g…

We are so excited to have the @uromigos back for kidney cancer board review & 2024 updates

First up with Localized RCC discussing risk factors, who needs genetic testing, who qualifies for adjuvant therapy…& who’s a faster swimmer btw Brian Rini, MD & Tom Powles

Just in Cancer Cell 👉Validation of the molecular clusters of the IMmotion151 trial in the JAVELIN Renal 101 dataset #kidneycancer : Excellent commentary highlighting these biomarkers by our fellow Chadi Hage Chehade 👇tinyurl.com/48px5rw8 GU Cancer Research Program @HuntsmanCancer OncoAlert UroToday.com KidneyCAN

Response assessment crudely telling regression%🔢 is missing the bigger picture for patients receiving immunotherapy.

💡Time to revise assessment methods to reflect the pattern👇🏾.

Different implications for the same response on chemo☢️🆚
immunotherapy.
📌nature.com/articles/s4138…

For patients who have completed 6 cycles of 177Lu-PSMA treatment and meet relevant PET criteria, the majority opinion (59%) supports re-treatment only if there was a response duration of more than 6 months.

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano…

Vitamin D appears to promote the immune response to cancer and the success of immunotherapy; now a mechanism is identified involving the gut microbiome interactions
science.org/doi/10.1126/sc…
science.org/doi/10.1126/sc…
Science Magazine Dr. Kathy McCoy Caetano Reis e Sousa The Crick

Wow! Congrats to the A031704 team and all of the patients! 5 years in the making. The power of the cooperative groups! Tian Zhang, MD, MHS Toni Choueiri, MD Alliance for Clinical Trials in Oncology NCICancerTrials Atish Choudhury, MD PhD Alan Tan

Part 2 of our discussion with the wonderful Dr. Larry Einhorn is out this week covering the Tx of Non-Seminoma including salvage regimens & the TIGER 🐯 trial, toxicities of Tx, as well as words of wisdom for trainees

podcasts.apple.com/us/podcast/two…

Just out in ESMO open ESMO - Eur. Oncology With 44.0 months of median follow-up nivolumab/cabozantinib continues to outperform sunitinib in M1 clear cell RCC. The 3 VEGF/TKI combinations have more similarities than differences and track each other with longer follow up gbr01.safelinks.protection.outlook.com/?url=https%3A%…

CARMENA showed no advantage of cytoreductive nephrectomy in metastatic RCC(OS HR 0.89 (95% CI .71- 1.10)). While retrospective case series show a benefit for nephrectomy due to selection. Meta-analysis magnifies the challenges with retrospective data. CN should usually be avoided

U.S. FDA approves Anktiva!

More options for patients with BCG UR NMIBC Bladder Cancer Advocacy Network IBCG

💡Timing⏱️of assessing response to #immunotherapy matters.

We underestimate how quickly immunotherapy works.👇🏾1️⃣2️⃣days with BOT/BAL #NestTrial 🪺all you see are immune cells🟣🟣in the biopsy.

At surgery➡️tumor is💯% dead; immune cells have left the party.

📸 RareCyte, Inc. #CRCSM

Adjuvant pembrolizumab shows a significant and clinically meaningful OS benefit in intermediate and high risk clear cell renal cancer for the 1st time (KN564). This further tips the balance towards giving adjuvant pembro in this setting NEJM Toni Choueiri, MD nejm.org/doi/full/10.10…

💫🌟 NCCN 2024 Prostate Cancer Guidelines Update 🌟💫
Zach Klaassen Rashid K. Sayyid
UroToday.com OncoAlert Advanced Prostate Cancer Consensus Conference urotoday.com/video-lectures…
🔹️ Major updates focus on the management of progressive M0 CSPC post-maximal pelvic therapy. 
🔹️ Introduction of enzalutamide, with or…

Preclinical data w/ KRAS G12D blocking drug, RMC-9805, looks promising & Ph 1 clinical trial ongoing. KRAS G12D mutation seen in several cancers & continues to be an unmet need. Great to see new options on the horizon. #JohnKnox #AACR24 KRASKickers